https://www.thebodypro.com/category/lopinavir-ritonavir-kaletra

Lopinavir/Ritonavir (Kaletra)

The Latest

lab testing
News

This Week in HIV Research: The Frustrating Relativity of Efficacy

March 26, 2020: Lopinavir/ritonavir falls short against COVID-19; impact of PrEP scale-up on HIV diagnoses; long-term cost-effectiveness of various HIV interventions; disparities in virologic suppression among young people.

By Barbara Jungwirth and Myles Helfand
The DAWNING Study photo illo
Features

DAWNING Study Casts New Light on the Details of Resistance

The findings will help providers manage patients who have known or potential resistance to NRTIs, but who we want to place on a simplified antiretroviral regimen.

By David Alain Wohl, M.D.
This Week in HIV Research: Looking Forward, Looking Back Img
People Who Use Drugs

This Week in HIV Research: Looking Forward, Looking Back

In our final installment of 2017, we intermingle forward-looking research with some retrospective analysis. We begin our four-study tour by joining researchers in Tennessee for an exercise in HIV outbreak prediction.

By Barbara Jungwirth and Myles Helfand
Promo Image
CROI (Conference on Retroviruses and Opportunistic Infections)

Long-Acting HIV Treatment: 5 Myths and Realities

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.

By Myles Helfand
Women on Lopinavir/Ritonavir-Based Regimens at Conception at Higher Risk of Preterm Delivery in UK Study Img
CROI (Conference on Retroviruses and Opportunistic Infections)

Women on Lopinavir/Ritonavir-Based Regimens at Conception at Higher Risk of Preterm Delivery in UK Study

HIV-positive pregnant women receiving lopinavir/ritonavir-based regimens were at higher risk of preterm delivery compared with those on NNRTI-based regimens.

By Polly Clayden for HIV i-Base
Slow But Steady Increase in Kidney Risk Observed With TDF, Atazanavir, Lopinavir Img
Kidney

Slow But Steady Increase in Kidney Risk Observed With TDF, Atazanavir, Lopinavir

Each additional year of tenofovir disoproxil fumarate, ritonavir-boosted atazanavir or lopinavir was independently linked to higher incidence of chronic kidney disease in a 23,905-person cohort with initially normal renal function.

By Mark Mascolini
Lopinavir/Ritonavir Pellets for Children Tentatively Approved by the FDA Img
News

Lopinavir/Ritonavir Pellets for Children Tentatively Approved by the FDA

On May 21, the U.S. Food and Drug Administration tentatively approved lopinavir/ritonavir 40/10-mg pellets for infants and young children less than 3 years old.

By Polly Clayden for HIV i-Base
Lopinavir/Ritonavir Superior to Nevirapine in Children Over 3 Years Old: IMPAACT P1060 Study Results Img
Conference Coverage

Lopinavir/Ritonavir Superior to Nevirapine in Children Over 3 Years Old: IMPAACT P1060 Study Results

Long-term virologic suppression was superior in children receiving lopinavir/ritonavir-based antiretroviral therapy compared with nevirapine-based regimens at five-year follow up in the IMPAACT P1060 trial.

By Polly Clayden for HIV i-Base
Promo Image
Bone

Kaletra + Raltegravir: Does Sparing Some Nukes Help Bones?

Once potent combination therapy for HIV (commonly called ART or HAART) is initiated, several clinical trials have found that bone mineral density tends to decrease, usually between 2% and 6%, and then stabilize. The reasons for this initial decrease ...

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange
Dual-Drug Therapy of Lopinavir/Ritonavir and Lamivudine Non-Inferior to Triple-Drug Therapy Img
Conference Coverage

Dual-Drug Therapy of Lopinavir/Ritonavir and Lamivudine Non-Inferior to Triple-Drug Therapy

A recent study revealed a surprising result: For the first time ever, an HIV treatment regimen consisting of two drugs was found to work just as well as a three-drug regimen.

By Warren Tong